These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20973483)

  • 1. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
    Shook BC; Rassnick S; Osborne MC; Davis S; Westover L; Boulet J; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Palmer D; Reyes M; Demarest K; Tang Y; Rhodes K; Jackson PF
    J Med Chem; 2010 Nov; 53(22):8104-15. PubMed ID: 20973483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
    Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF
    J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
    Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC
    Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists.
    Drabczyńska A; Zygmunt M; Sapa J; Filipek B; Müller CE; Kieć-Kononowicz K
    Arch Pharm (Weinheim); 2011 Jan; 344(1):20-7. PubMed ID: 21213348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
    Neustadt BR; Hao J; Lindo N; Greenlee WJ; Stamford AW; Tulshian D; Ongini E; Hunter J; Monopoli A; Bertorelli R; Foster C; Arik L; Lachowicz J; Ng K; Feng KI
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1376-80. PubMed ID: 17236762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.
    Zhang X; Rueter JK; Chen Y; Moorjani M; Lanier MC; Lin E; Gross RS; Tellew JE; Williams JP; Lechner SM; Markison S; Joswig T; Malany S; Santos M; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J; Slee DH
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1778-83. PubMed ID: 18329269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a New Series of Potent Adenosine A
    Yang Z; Li L; Zheng J; Ma H; Tian S; Li J; Zhang H; Zhen X; Zhang X
    ACS Chem Neurosci; 2016 Nov; 7(11):1575-1584. PubMed ID: 27569066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.
    Endo K; Deguchi K; Matsunaga H; Tomaya K; Yamada K
    Bioorg Med Chem; 2014 Jun; 22(12):3072-82. PubMed ID: 24815000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
    Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
    Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
    Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
    J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
    Slee DH; Zhang X; Moorjani M; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Wen J; O'Brien Z; Saunders J
    J Med Chem; 2008 Feb; 51(3):400-6. PubMed ID: 18189346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
    Pinna A; Volpini R; Cristalli G; Morelli M
    Eur J Pharmacol; 2005 Apr; 512(2-3):157-64. PubMed ID: 15840400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Chen L; Zhang J; Petter RC
    J Med Chem; 2004 Aug; 47(17):4291-9. PubMed ID: 15294001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
    Vu CB; Shields P; Peng B; Kumaravel G; Jin X; Phadke D; Wang J; Engber T; Ayyub E; Petter RC
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4835-8. PubMed ID: 15341934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.
    Shah U; Lankin CM; Boyle CD; Chackalamannil S; Greenlee WJ; Neustadt BR; Cohen-Williams ME; Higgins GA; Ng K; Varty GB; Zhang H; Lachowicz JE
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4204-9. PubMed ID: 18558486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.